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Carvedilol, a third generation non-selective adrenoreceptor blocker, is widely used in
cardiology. Its action has been proven to reach beyond adrenergic antagonism and involves
multiple biological mechanisms. The interaction between carvedilol and endogenous
gasotransmitter hydrogen sulfide (H2S) is unknown. The aim of the study is to assess theinfluence of carvedilol on the H2S tissue level in mouse brain, liver, heart and kidney. Twentyeight SJL strain female mice were administered intraperitoneal injections of 2.5 mg/kg
b.w./d (group D1, n = 7), 5 mg/kg b.w./d (group D2, n = 7) or 10 mg/kg b.w./d of carvedilol
(group D3, n = 7). The control group (n = 7) received physiological saline in portions of the
same volume (0.2 ml). Measurements of the free tissue H2S concentrations were performedaccording to the modified method of Siegel. A progressive decline in H2S tissueconcentration along with an increase in carvedilol dose was observed in the brain (12.5%,
13.7% and 19.6%, respectively). Only the highest carvedilol dose induced a change in H2Stissue level in the heart  an increase by 75.5%. In the liver medium and high doses of
carvedilol increased the H2S level by 48.1% and 11.8%, respectively. In the kidney, group D2showed a significant decrease of H2S tissue level (22.5%), while in the D3 group the H2Sconcentration increased by 12.9%. Our study has proven that carvedilol affects H2S tissueconcentration in different mouse organs.
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Carvedilol, a third generation non-selective ad-
renoreceptor blocker, is widely used in cardiology
and general practice in the treatment of chronic
diseases like congestive heart failure and arterial
hypertension (CHAKRABORTY et al. 2010). The
action of carvedilol has been proven to reach be-
yond adrenergic antagonism and comprises i.a. an-
tioxidant activity, calcium channel blockade and
nitric oxide (NO) production enhancement (KOSTKA-
-JEZIERNY & TYKARSKI 2009). On the other hand,
endogenously formed ‘gasotransmitter’ hydrogen
sulfide (H2S) has been identified as a crucial regu-
lator of circulatory, nervous, gastrointestinal and
excretory systems. Altered production of H2S was
observed in arterial hypertension, myocardial ische-
mia and atherosclerosis (£OWICKA & BE£TOWSKI
2007). The interaction between carvedilol and en-
dogenous H2S is unknown.
The aim of the study is to assess the influence of
carvedilol on the endogenous tissue H2S concen-
trations in mouse brain, heart, liver and kidney.
Material and Methods
Animals
Twenty eight SJL strain female mice (11-12 week
old individuals) of approximately 20 g weight were
involved in the study. The animals were housed
under standard laboratory conditions and had free
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access to water and food. They were kept at a tem-
perature of 22-24°C with a light/dark cycle of 12 h.
Study protocol
A non-selective lipophilic â-blocker / á-1 blocker
carvedilol (Avedol, Polpharma, Poland) was dis-
solved in physiological saline. The study design
comprised intraperitoneal injections of 2.5 mg per kg
of body weight of carvedilol daily (group D1, n = 7),
5 mg per kg of body weight of carvedilol daily
(group D2, n = 7) or 10 mg per kg of body weight of
carvedilol daily (group D3, n = 7) for 5 consecutive
days at the same time of day (10:30 am), each ad-
ministration consisted of 0.2 ml of the solution.
The control population (n = 7) received intraperi-
toneally physiological saline in portions of the
same volume. The individuals were randomly as-
signed to each group. The animals tolerated the ap-
plied doses of carvedilol well and remained in
good condition till the end of the experiment.
Measurements of the free tissue H2S concentration
were performed by the use of the modified method
of Siegel (SIEGEL 1965; SOMOGYI et al. 2008).
The study has been performed in accordance with
the guidelines for the care and use of laboratory
animals accepted by Bioethical Committee of the
Jagiellonian University Medical College (Kraków,
Poland).
Tissue sample preparation
Two hours after the last drug or physiological sa-
line injection the animals were killed by cervical
dislocation, their brains, hearts, livers and kidneys
were quickly removed, homogenized with 0.01 mol/l
sodium hydroxide (NaOH): brain tissue in propor-
tion of 1 to 4, liver and kidney of 1 to 5 and heart of
1 to 10 and frozen. Then 50% trichloroacetic acid
(TCA) was added (0.5 ml to 2 g of brain or liver
samples in tight capsules of 3 ml and 0.25 ml to 1 g
of heart or kidney sample in tight capsules of 2 ml),
the suspension was shaken and centrifuged. Sub-
sequently, 1.5 ml brain or liver and 0.75 ml heart or
kidney supernatant samples were moved to 2 ml tight
capsules with 0.15 ml or 0.075 ml of 0.02 mol/l
N,N-dimethyl-p-phenyl-diamine sulfate in 7.2 mol/l
hydrochloric acid (HCl), then 0.15 ml or 0.075 ml
of 0.03 mol/l iron (III) chloride (FeCl3) in 1.2 mol/l
HCl portions were added, respectively. After 20
minutes in darkness the content was shaken for 1
minute with 1 ml of chloroform.
H2S tissue concentration measurements
Absorbance was measured at 650 nm with the
Varian Cary 100 spectrophotometer. A standard curve
was prepared with an iodometrically determined
0.0001 mol/l sodium sulfide (Na2S) solution. For
each group of animals four concurrent analyses of
each analyzed tissue type were performed.
Statistical analysis
Statistical analysis was performed within the R
Environment by the Student’s t-test and univariate
analysis of variance (ANOVA). Statistical signifi-
cance was considered when P<0.05.
Results and Discussion
Progressive H2S tissue concentration decline was
observed in the brain along with a rising carvedilol
dose (by 12.5%, 13.7% and 19.6%, respectively).
In the heart only the highest carvedilol dose in-
duced H2S tissue level change, but the increase
was spectacular, reaching 75.5%. In the liver, me-
dium and high doses altered the H2S concentration
– 5 mg/kg b.w./d of carvedilol increased the H2S
level by 48.1% and 10 mg/kg b.w/d by 11.8%. In
the kidney, the group D2 showed a significant de-
crease of H2S tissue level (22.5%), while in the D3
group H2S concentration increased by 12.9%. In
the variance analysis for each tissue type only H2S
concentration changes within the heart and brain
were statistically significant (Table 1). Noteworthy,
each organ has different metabolism, paracrine and
endocrine regulation, and specific transmitter interac-
tions, thus variable changes of H2S concentrations
only confirm this complexity and heterogeneity.
Carvedilol’s therapeutic actions could not be
fully explained by adrenoreceptor blockade. Nu-
merous studies have provided evidence that carve-
dilol has various other properties including
antioxidant action, calcium channel antagonism,
anti-inflammatory actions: fall in interleukin-1
(IL-1), interleukin-6 (IL-6), c-reactive protein (CRP)
and tumor necrosis factor-á (TNF-á), direct inhi-
bition of transcription factors like NF-êB, low den-
sity lipoproteins (LDL) oxidation; stabilization of
atherosclerotic plaques by decreasing intercellular
adhesion molecule-1 (ICAM-1) and activity of ma-
trix metalloproteinases 2 and 9 (MMP-2, MMP-9);
prevention of endothelial and myocardium apop-
tosis, reversal of cardiac remodeling in chronic
heart failure and endothelin-1 (ET-1) suppression
(BELLENGER et al. 2004; KALINOWSKI et al. 2003;
KOSTKA-JEZIERNY & TYKARSKI 2009; ROMEO et al.
2000; RUFFOLO et al. 1993). Moreover, the major
proportion of carvedilol’s biological action, espe-
cially regarding hypotensive and vascular effects,
seems to be mediated by NO, whose level rises due
to endothelial nitric oxide synthase (NOS) stimu-
lation (AFONSO et al. 2006).
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H2S is endogenously formed from L-cysteine in
several enzymatic reactions catalyzed by cystathio-
nine â-synthase (CBS), cystathionine ã-lyase (CSE)
and 3-mercaptopyruvate sulfurtransferase (3MST),
and in non-enzymatic pathways in many tissues.
Cytoplasmatic bound sulfur is postulated to absorb
and store exogenously applied and endogenously
produced H2S which is released from the bound
sulfur pool in the presence of physiologic concen-
trations of glutathione and cysteine in slightly al-
kaline conditions (ISHIGAMI et al. 2009). H2S acts
as a ‘gasotransmitter’ and serves as a co-modulator
of various physiological and pathophysiological
processes such as regulation of vascular tone,
myocardial contractility, neurotransmission and
perception (FIORUCCI et al. 2006; SHIBUYA et al.
2009). Its biological action comprises numerous
intracellular mechanisms including adenosine tri-
phosphate (ATP)-sensitive potassium channels
(KATP) stimulation, sulfhydration of different pro-
teins and maintaining protein–SH groups in the re-
duced state, reaction with reactive oxygen and
nitrogen species (ROS and RNS) (£OWICKA &
BE£TOWSKI 2007; SUN et al. 2008). H2S interacts
with carbon monoxide (CO) and nitric oxide (NO)
in a number of ways including affecting each
other’s synthesis and biological responses within
target tissues. All these three gases bind to haemo-
globin and impede mitochondrial oxidative phos-
phorylation by inhibiting cytochrome c oxidase
(LI et al. 2009). Analogically to carvedilol, H2S
decreases IL-6, TNF-á levels, reduces the activa-
tion of NF-êB complex and the activity of MMP-2
and MMP-9 (OH et al. 2006; SEN et al. 2009;
SODHA et al. 2009).
Our study has shown that carvedilol’s action in-
volves H2S, probably via its production rate altera-
tion and release with possible NO share as one of
the mechanisms. Some of the biological effects of
the beta-blocker and H2S are common. It is un-
known whether H2S mediates any of them and to
what extent carvedilol’s biology is dependent on
the messenger, since research dedicated to the is-
sue has not been done. In the heart, the cardiopro-
tective effects of H2S have been demonstrated to
involve opening of KATPchannels as well as effects
of preserving mitochondrial structure and function
(ELROD et al. 2007). It might be an accessory ef-
fect to NO beneficial impact on intracellular tran-
scription factors resulting in increased expression
of cardioprotective proteins like superoxide dismu-
tase (SOD), inducible NOS (iNOS), cyclooxygenase-2
(COX-2) and heat shock proteins (DAWN & BOLLI
2002). In hepatology, carvedilol appears to be a
potentially viable option for treating portal hyper-
tension along with angiotensin-converting en-
zyme inhibitors (ACEI) (HEMSTREET 2004). H2S
regulates perfusion pressure in normal and cir-
rhotic liver in a NO-independent manner; NO and
H2S are released by different cellular sources and
their hemodynamic effects involve different cellu-
lar targets. H2S generation in cirrhosis is decreased
due to a reduced expression/activity of CSE in he-
patic stellate cells (HSC) – one of the main sources
of H2S in the liver (FIORUCCI et al. 2005). In our
previous studies a tissue specific ACEI ramipril
also enhanced the H2S tissue level in the liver,
heart and kidney (WILIÑSKI et al. 2010; WILIÑSKI
et al. 2008). In kidneys H2S has been recognized as
an important regulator of renal function affecting
both vascular and tubular actions (XIA et al. 2009).
Some studies with carvedilol demonstrate attenu-
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Table 1
Hydrogen sulfide (H2S) tissue concentration in mouse brain, heart, liver and kidney follow-
ing the administration of 2.5 mg/kg b.w. per day, 5 mg/kg b.w. per day or 10 mg/kg b.w. per













Brain 2.55 ± 0.04 2.23 ± 0.05** 2.20 ± 0.05** 2.05 ± 0.05*** <0.001
Heart 6.78 ± 0.06 5.91 ± 0.15 6.61 ± 0.14 11.90 ± 0.12*** <0.001
Liver 4.14 ± 0.04 4.17 ± 0.08 6.13 ± 0.14*** 4.63 ± 0.10** 0.22
Kidney 8.66 ± 0.19 8.45 ± 0.17 6.71 ± 0.08*** 9.78 ± 0.18*** 0.21
*P<0.05 for given group vs control group, **P<0.01 for given group vs control group, ***P<0.001 for given group vs control
group
ated increases in albuminuria as well as reduction
in cardiovascular events in chronic kidney disease
patients with hypertension (BAKRIS et al. 2006).
Carvedilol also protected against the renal mito-
chondrial toxicity induced by cisplatin and
daunorubicin-induced cardiotoxicity and nephro-
toxicity in rats (AROZAL et al. 2010; RODRIGUES
et al. 2010).
H2S acts as a neuromodulator as well as an intra-
cellular messenger in the central nervous system.
Its perturbed metabolism has been investigated in
many neurological disorders including Alzheimer’s
disease (QU et al. 2008). Recently, carvedilol was
found to improve neuronal transmission and at-
tenuate brain oligomeric beta-amyloid content and
cognitive deterioration in two mouse models of
Alzheimer’s disease (WANG et al. 2010). Analogi-
cally, non-steroidal anti-inflammatory drugs were
also demonstrated to exert some anti-amyloidogenic
effects and to affect H2S biology (BILSKA et al.
2010; SREBRO et al. 2006).
In conclusion, carvedilol affects the H2S tissue
concentrations in mouse brain, heart, liver and kid-
ney. The involvement of H2S makes the biological
action of carvedilol more complex and opens new
fields for investigation for both of them in neurol-
ogy, cardiology, hepatology and nephrology. Several
biotechnology companies are already developing
H2S-based therapeutic compounds, and there are
ongoing clinical trials investigating the therapeu-
tic potential of H2S (PREDMORE & LEFER 2010).
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